The Marlborough, Mass.-based company posted profits of $112.9 million, or 41¢ per share, on sales of $824 million for the three months ended June 30, seeing 89.7% growth on the bottom-line while sales grew 2.2% when compared to the same period during the previous year.
Adjusted to exclude one-time items, earnings per share were 58¢, just ahead of the 56¢ consensus on Wall Street where analysts expected too see sales of $800.4 million, which the company handily topped.
“We posted good financial results in the third quarter, with both revenue and EPS exceeding our guidance. Our breast health and international businesses continued their strong recent performance. And surgical and Cynosure both showed sequential improvement, in line with our expectations,” prez & CEO Steve MacMillan said in a press release.
The company lifted its full-year 2018 revenue guidance to between $3.205 billion and $3.22 billion from previous guidance of between $3.18 billion and $3.21 billion. Non-GAAP EPS estimates also got a slight shift, moving from between $2.22 and $2.27 to between $2.24 and $2.26.
For the fourth quarter, Hologic said it expects to post sales of between $800 million and $815 million with non-GAAP EPS of between 58¢ and 60¢.
Shares in Hologic haven’t moved in after-hours trading as of 5:00 p.m. after closing at $42.91.
Yesterday, Hologic said that a US International Trade Commission Administrative Law Judge ruled in their favor in an investigation into a patent infringement complaint filed against Fujifilm Holdings (TSE:4901).